J 2019

The legal framework for European cervical cancer screening programmes

MÁJEK, Ondřej, Ahti ANTTILA, Marc ARBYN, Evert Ben VAN VEEN, Birgit ENGESAETER et. al.

Základní údaje

Originální název

The legal framework for European cervical cancer screening programmes

Autoři

MÁJEK, Ondřej (203 Česká republika, garant, domácí), Ahti ANTTILA (246 Finsko), Marc ARBYN (56 Belgie), Evert Ben VAN VEEN (528 Nizozemské království), Birgit ENGESAETER (578 Norsko) a Stefan LONNBERG (246 Finsko)

Vydání

European journal of public health, OXFORD, OXFORD UNIV PRESS, 2019, 1101-1262

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10103 Statistics and probability

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.391

Kód RIV

RIV/00216224:14110/19:00109669

Organizační jednotka

Lékařská fakulta

UT WoS

000463809200027

Klíčová slova anglicky

European cervical cancer screening programmes

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 16. 5. 2019 14:33, Soňa Böhmová

Anotace

V originále

Background: A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries. Methods: An electronic questionnaire including questions on governance, decision-making structures and legal framework was developed. The primary responses were collected by September 2016. Results: We sent the questionnaire to representatives of 35 European countries (28 countries of the EU, with the United Kingdom included as 4 countries; 4 EFTA member countries: Iceland, Liechtenstein, Norway, and Switzerland); responses were collected from 33 countries. The legal framework makes it possible to personally invite individuals in 29 countries (88%). Systematic screening registration in an electronic registry is legally enshrined in 23 countries (70%). Individual linkage of records between screening and cancer registries is allowed in 19 of those countries. Linkage studies involving cancer and screening registries have been conducted in 15 countries. Conclusion: Although the majority of EU/EFTA countries have implemented population-based screening, only half of them have successfully performed record linkage studies, which are nevertheless a key recommendation for quality assurance of the entire screening process. The European legislation is open to the possibility of using health data for these purposes; however, member states themselves must recognize the public interest to create a legal basis, which would enable all the necessary functions for high-quality cancer screening programmes.